WallStSmart

Marvell Technology Group Ltd (MRVL)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Marvell Technology Group Ltd generates 154% more annual revenue ($8.19B vs $3.22B). MRVL leads profitability with a 32.6% profit margin vs 16.9%. MRVL appears more attractively valued with a PEG of 1.84. WST earns a higher WallStSmart Score of 67/100 (B-).

MRVL

Strong Buy

66

out of 100

Grade: B-

Growth: 8.7Profit: 8.0Value: 3.7Quality: 7.0
Piotroski: 5/9Altman Z: 1.80

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MRVL.

WSTSignificantly Overvalued (-33.5%)

Margin of Safety

-33.5%

Fair Value

$184.38

Current Price

$297.59

$113.21 premium

UndervaluedFair: $184.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRVL4 strengths · Avg: 9.3/10
Profit MarginProfitability
32.6%10/10

Keeps 33 of every $100 in revenue as profit

EPS GrowthGrowth
106.3%10/10

Earnings expanding 106.3% YoY

Market CapQuality
$144.42B9/10

Large-cap with strong market position

Revenue GrowthGrowth
22.1%8/10

Revenue surging 22.1% year-over-year

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

MRVL4 concerns · Avg: 3.5/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Price/BookValuation
9.8x4/10

Trading at 9.8x book value

Altman Z-ScoreHealth
1.804/10

Grey zone — moderate risk

P/E RatioValuation
53.8x2/10

Premium valuation, high expectations priced in

WST2 concerns · Avg: 3.0/10
P/E RatioValuation
39.0x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
2.912/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : MRVL

The strongest argument for MRVL centers on Profit Margin, EPS Growth, Market Cap. Profitability is solid with margins at 32.6% and operating margin at 18.7%. Revenue growth of 22.1% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : MRVL

The primary concerns for MRVL are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 53.8x leaves little room for execution misses.

Bear Case : WST

The primary concerns for WST are P/E Ratio, PEG Ratio.

Key Dynamics to Monitor

MRVL carries more volatility with a beta of 1.82 — expect wider price swings.

MRVL is growing revenue faster at 22.1% — sustainability is the question.

MRVL generates stronger free cash flow (259M), providing more financial flexibility.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WST scores higher overall (67/100 vs 66/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Marvell Technology Group Ltd

TECHNOLOGY · SEMICONDUCTORS · USA

Marvell Technology, Inc. designs, develops, and sells analog, mixed-signal, digital signal processing, and integrated and independent integrated circuits. The company is headquartered in Wilmington, Delaware.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?